Modified saRNA Shows Promise for More Effective Vaccines

Boston University researchers successfully modified self-amplifying RNA (saRNA) to enhance its effectiveness and reduce side effects. Their innovative approach involves altering the chemical structure of saRNA, allowing it to replicate itself multiple times within a cell. This modification results in increased protein production at lower doses, potentially leading to more potent and longer-lasting vaccines. 

The team's modified saRNA vaccine showed promising results in protecting mice against COVID-19, performing as well as current mRNA vaccines but at a significantly lower dose. "Our reaction to that was a lot of excitement, but also the normal scientist thinking, 'Did we do this right?'" Joshua McGee, first author of the paper published in Nature Biotechnology, recalls.

Beyond vaccines, this technology holds potential for treating genetic disorders and various cancers. As senior author Wilson W. Wong explains, "At the end of the day, this is a protein-producing system. A gene-delivery system." The modified saRNA could be programmed to produce missing genes or replace defective ones in genetic disorders, or to produce anticancer drugs for diseases requiring high doses of protein.

While years of testing lie ahead before human trials can begin, this breakthrough opens new possibilities in genetic engineering and therapeutic applications. McGee reflects on the importance of perseverance in scientific research: "There are a lot of publications out there that suggested research on saRNA would also fail. This made me realize that it's okay to try things that other people think might fail, because, who knows, they could be wrong."